1. Acute tubular necrosis (ATN) with acute renal failure (ARF) was induced in rats with (a) a combination of subcutaneous (s.c.) cephaloridine 500 mg/kg, frusemide 50 mg/kg and 4 ml/kg of 50% (v/v) glycerol in sterile water, (b) S.C. cephaloridine 1500 mg/kg, (c) S.C. mercuric chloride 2.0 and 4.7 mg/kg and (d) both S.C. and intramuscular glycerol (10 ml/kg in sterile water).
1971
; Linton, Bailey & Turnbull, 1972) . This damage is increased by the concurrent administration of frusemide Dodds & Foord, 1970; Linton et al., 1972) .
With the knowledge that cephaloridine nephrotoxicity is potentiated by the addition of frusemide the present study was undertaken to assess the effects of pretreating rats for varying periods with frusemide before administering cephaloridine and other known nephrotoxic drugs. Rather than observing potentiation, striking protection against ATN and ARF was demonstrated.
MATERIALS A N D METHODS
Male albino Wistar rats weighing between 140 and 190 g were used. All animals received a commercial diet free from antibiotics (Purina Rat Chow, 0.42% sodium) and were given unlimited access to tap water. All animals were weighed on the same set of scales prior to every injection and again before being killed. For each experiment, a group of rats were given five subcutaneous (s.c.) 0-8 ml doses of 5% (w/v) dextrose solution every 12 h; these rats served as controls. Littermates received five S.C. doses of frusemide 50 mg/kg every 12 h and are hereafter referred to as the 'pretreated' groups.
To assess the 24 h water intake and urine volume, and the glomerular filtration rate (GFR) (as measured by the 24 h clearance of endogenous creatinine), groups of control and pretreated rats were placed in individual metabolic cages immediately following the fifth injection of dextrose or frusemide. All urine was collected into sealed containers. Similar control and pretreated groups of animals were killed 12 h after the Mth S.C. injection of dextrose or frusemide to determine the blood urea nitrogen (BUN), plasma creatinine (AutoAnalyzer), serum sodium and potassium (IL Flame Photometer), haematocrit (Microhaematocrit), urine osmolality (Precision Osmometer) and the plasma renin activity (PRA) as measured indirectly using a radioimmunoassay of generated angiotensin 1 (Schwarz-Mann).
Twelve hours after the fifth injection of dextrose or frusemide, control and pretreated groups of rats were challenged with one of the following nephrotoxic drugs or combination of drugs:
1. A S.C. combination of cephaloridine 500 mg/kg, frusemide 50 mg/kg, and 4 ml/kg of 50% (v/v) glycerol in sterile water. This triple challenge has been shown previously by us to produce predictable ATN with ARF.
2. A S.C. injection of cephaloridine in a dose of 1O00, 1250 or 1500 mg/kg. This latter dose of cephaloridine results in consistent ATN but little ARF.
3. One or both of the above two nephrotoxic challenges were repeated after the following modifications of the pretreatment regime:
(a) Reduction of the number of pretreatment injections of frusemide (50 mg/kg) to 4, 3, 2 and 1. 6. The same dose of glycerol as in (4) but injected intramuscularly (i.m.) in divided doses into each hind limb (Oken, Arce 8z Wilson, 1966) .
At 48 h after the nephrotoxic insult, all animals were lightly anaesthetized with ether, and blood taken from the inferior vena cava for estimation of BUN, plasma creatinine and serum electrolytes. In some animals, PRA was measured as described. For each experiment, PRA was measured in duplicate, on the same day, at the same plasma dilution and using the same batch of assay material. All assays were performed at a pH of 7.4, and were processed without knowledge of the experimental conditions. The % binding of a known amount of labelled angiotensin 1 to a constant amount of anti-angiotensin 1 antibody varied in individual assay kits from 42.2 to 503% with a mean of 47.3 f 1.2%. The coefficient of variation (standard deviationlmean expressed as a % was calculated to facilitate comparison between rats) for duplicate estimations of PRA on all individual rats varied from 0 to 26.3% with a mean of 8.8 & 1.6%. When possible, urine was obtained from the bladder and the osmolality measured. All rat kidneys were fixed in Zenker's solution for 24 h then bisected longitudinally. Sections were embedded in paraf6n and cut at 4 pm and stained with Haematoxylin and Eosin.
Histopathological changes
1. Microfoci of acute tubular necrosis. This is a diffuse multifocal lesion of the proximal convoluted tubules showing slight tubular dilatation, with eosinophilic granular intraluminal casts. Isolated tubular epithelial cells show cytoplasmic eosinophilia and nuclear pyknosis and a few have sloughed into the lumen.
2. Moderate acute tubular necrosis. A much larger percentage of proximal tubules are dilated, the casts are more amphophilic, hyaline-like and have sharp margins. Many more tubular cells are necrotic, and there are focal areas of regeneration within tubules. A few casts may be seen in the distal and collecting tubules, but there is no necrosis.
3. Severe acute tubular necrosis. There is pronounced dilatation of virtually all the proximal convoluted tubules and necrosis of tubular epithelial cells is extensive. Hyaline-like casts are seen in all tubules, although necrosis is confined to the proximal convoluted tubule. There are widespread areas of regenerating proximal convoluted tubules.
It was possible to pick out those sections which had been treated with mercuric chloride because of the virtually pathognomonic pattern (Di Bona et al., 1971) of band-like necrosis of proximal convoluted tubules of the inner cortex. The difference between moderate and severe renal tubular necrosis associated with mercuric chloride was mainly one of degree and extent of inner cortical involvement and the presence of casts in the distal convoluted tubules in the severe variety.
To assess the serum levels of cephaloridine in the control and pretreated rats after both the triple challenge and the nephrotoxic (1500 mg/kg) dose of cephaloridine alone, groups of two to four rats were killed (under light ether anaesthesia) at intervals from 3 to 6 h after the challenges and blood taken from the inferior vena cava. Duplicate aliquots of the separated serum were stored without preservative at -20°C. Cephaloridine was assayed (under code) in serial dilutions using a cylinder cup technique (Bryant, 1968) . The test organism was Bacillus subtilis A.T.C.C. 6633. The urinary excretion of cephaloridine was measured in groups of control and pretreated rats by placing them in individual metabolic cages immediately following the triple challenge or cephaloridine (1500 mg/kg) alone. The urine was collected into a sealed container which remained at room temperature. After 24 h the container was re-moved, the urine volume measured and duplicate aliquots of urine stored and assayed as above.
The statistical correlations were made using either the Student's t-test or the chi square test with Yates' correction, applied if necessary. All values given in the tables are means L-standard error of the mean. The half-life of cephaloridine in serum was determined using the method of least squares (Kunin & Finland, 1958) .
R E S U L T S
Efects of pretreating rats with frusemide To define differences at the time of challenge between the control and pretreated rats, a group of each were killed 12 h after the fifth dose of dextrose or frusemide. The pretreated animals were moderately hydrated, had a significantly lower serum potassium level (P < 0.001) and an elevated PRA (P<O.001) compared with controls ( Table 1) . Renal histology was normal in all rats. All variables for the control rats were not significantly different from the normal values obtained in our laboratory for male Wistar rats in the same weight range and eating the same diet. Pretreated rats had a significantly lower GFR of 494L-63 p1 min-' 100 g -' compared with 649 L-25 pl min 100 g -' for the control animals (0.05 > P > 0*02), when studied for the 24 h period immediately following the fifth injection of frusemide and dextrose respectively ( Table 2) .
Efect of frusemide pretreatment on a combination challenge of subnephrotoxic doses of cephaloridine and glycerol with frusemide, or a nephrotoxic challenge of cephaloridine alone
1. The control group of rats given the S.C. triple challenge of cephaloridine 500 mg/kg, frusemide 50 mg/kg and 4 ml/kg of 50% glycerol in sterile water developed unequivocal ATN and ARF, and confirmed previous studies . The rats pretreated with five doses of frusemide showed no renal damage histologically, were rehydrated, and the BUN and plasma creatinine levels were in the normal range (Table 3) .
2. No renal damage was produced in any control or pretreated rat given loo0 or 1250 mg/kg of S.C. cephaloridine. A cephaloridine dosage of 1500 mg/kg, however, resulted in ATN in twenty of twenty-five control rats; in the pretreated group only one of twenty-five rats showed histological damage. Despite the striking histological differences between the control and pretreated rats, the biochemical evidence indicating ARF was considerably less marked and did not attain statistically significant levels. The PRA was measured in twelve rats from each group and although the mean value was higher at the time of death in the control animals (i.e. in the group developing ATN) this difference was not significant ( Table 3) .
Serum levels of cephaloridine in control and pretreated rats a f e r triple challenge and cephaloridine (1 500 mglkg) alone
The pretreated rats had a higher serum cephaloridine level at 4, 1 and 2 h following the triple challenge than the control animals ( Fig. la) , the difference at 2 h being significant (0*05>P> 0.02). At 3 h the control rats had a significantly higher mean serum level than the pretreated group (P<O.Ol). The serum half-life calculated for the control group was 57 min and for the pretreated group 78 min.
After the challenge of cephaloridine (1 500 mg/kg) the mean peak serum cephaloridine level reached 420 pg/ml in the control rats but only 280 pg/ml in the pretreated animals. The serum levels were higher at 1 and 2 h in the pretreated rats than in the controls, but none of the values 
N.S.,
Not significant. varied significantly because of the wide range of levels within individual groups (Fig. 1 b) . The serum half-life for the control rats was 52 min and for the pretreated group 66 min.
Urinary levels of cephaloridine in control and pretreated rats after triple challenge and cephaloridine (1 500 mglkg) alone
The pretreated rats excreted 52% of the administered dose of cephaloridine within 24 h compared with 38% for the control animals; the difference in the mean amount of excreted cephaloridine per 100 g rat during this period did not attain statistically significantly levels (0.1 >P>0.05). The mean concentration of cephaloridine in the 24 h urine was higher in the pretreated rats than the controls but the difference was not significant (0.1 >P>O.O5) ( Table 4) .
Following the challenge with cephaloridine 1500 mg/kg the pretreated animals excreted 56% of the administered dose compared with 43% for the control animals. The difference in the quantity of drug excreted in 24 h in the two groups, when adjusted to body weight, again did not reach statistically significant levels (0.1 > P > 0.05). The concentration of cephaloridine in the 24 h urine was similar in both groups of rats (Table 4) .
Protective effect of variations in frusemide pretreatment regime
To investigate how many pretreatment doses of frusemide were necessary to confer protection against the ATN and ARF produced by the triple challenge, groups of rats were challenged with this combination after receiving four, three, two or one pretreatment doses of frusemide (50 mg/kg); the last dose in each case being given 12 h before the nephrotoxic insult. These rats were compared with a control group who received one to four S.C. doses of 5% dextrose. A reduction in the number of pretreatment doses of frusemide from five to one did not result in any diminution in the protection conferred against ATN and ARF. In each group the protection against ATN was complete. The control group of rats in this experiment showed a comparable degree of ATN (twenty of twenty-five rats) compared with the previous control group who received the triple challenge, but the former inexplicably showed less evidence of associated renal functional impairment (mean BUN 19.3 1.7 mg/100 ml); nevertheless, comparison of the mean BUN of this control group with each of the pretreated groups showed significant differences (for all groups P<O*001). The PRA was 21-72 3.0 ng ml h -' in the control rats and 14.42 1-7 ng ml -' h-' in those rats who received a single 50 mg/kg dose of frusemide (0.05 > P > 0.02).
When the single pretreatment dose of frusemide was reduced progressively in groups of rats from 50 to 10 mg/kg, protection against the ATN and ARF following the triple challenge was again conferred, although one of five rats pretreated with frusemide 20 mg/kg developed moderate ATN, and one of each group of five rats receiving a single pretreatment dose of 50 mg/kg, 30 mg/kg and 10 mg/kg of frusemide respectively had microfoci of ATN present.
To assess the effect of a diminishing time interval between a single pretreatment injection of frusemide and a challenge with cephaloridine 1500 mg/kg, groups of rats were given a single injection of frusemide (50 mg/kg). At the same time one of these groups of animals was given an injection of cephaloridine (1 500 mg/kg), together with frusemide. In the remaining groups an interval of 1-6 h elapsed before administering the cephaloridine. A control group of rats received 1500 mg/kg of cephaloridine alone. From Table 5 it can be seen that frusemide given 5 or 6 h before the cephaloridine afforded protection against ATN in all but one rat; with a reducing interval from 4 h between the two injections the amount of histological damage increased until extensive ATN and moderate ARF were observed in eight of ten rats given the drugs together.
Effect of pretreatment with frusemide on nephrotoxic challenges of mercuric chloride
Groups of control and pretreated [five injections of frusemide (50 mg/kg) at 12 h intervals] rats were prepared as in the previous experiments. Following a challenge with 2.0 mg/kg of S.C. mercuric chloride all control rats developed moderate or severe ATN and moderate ARF (mean BUN 69214.5 mg/lOO ml), compared with only four of the ten pretreated animals (mean BUN 25k3.9 mg/100 ml). The mean values for the BUN and plasma creatinine were both significantly lower (P<O.Ol) in the pretreated rats (Table 6 ). At the time of death the mean PRA was 8.7 f2.0 ng ml -' h h -' in the control animals (0*05>P>0.02). When the S.C. dose of mercuric chloride was increased to 4.7 mg/kg all control rats developed severe extensive ATN and ARF (mean BUN 180.3k7.3 mg/lOO ml) while the pretreated rats had more moderate but still extensive histological damage and severe ARF (mean BUN 152-3 k22.4 mg/100 ml) ( Table 6 ).
Effect of pretreatment with frusemide on nephrotoxic challenges using glycerol When S.C. glycerol in high dosage [I0 ml/kg of 50% (v/v) glycerol in sterile water] was used alone as the nephrotoxic insult, extensive pathological changes were found in both the control animals and those pretreated with frusemide. Compared with all the above experiments the ATN and ARF was more severe in the pretreated animals ( Table 7 ). The experiment was repeated with the same dose of glycerol given intramuscularly and again pretreatment with frusemide made the ATN and ARF more severe ( Table 7) . The ATN and ARF induced by the i.m. glycerol was more marked than following S.C. glycerol, particularly in the pretreated animals. The PRA was not significantly different in the control or pretreated rats after either S.C. or i.m. glycerol (Table 7 ). All rats given glycerol became ill and lost weight and the latter was more marked at the time of death in the frusemide pretreated groups; in the experimental models other than glycerol the frusemide pretreated rats tended to regain weight (i.e. rehydrate) between the time of challenge and the time of death (Tables 3, 5, 6 and 7).
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DISCUSSION
The striking finding in this study was the protection conferred by frusemide pretreatment against the ATN and ARF produced by a triple challenge consisting of subnephrotoxic doses of cephaloridine, glycerol and frusemide, and against the ATN and slight ARF produced by nephrotoxic doses of cephaloridine alone. Protection against ATN and ARF induced by mercuric chloride was also demonstrated, but was less marked. Conversely, pretreatment with frusemide increased the extent of ATN and the degree of ARF induced by glycerol. These observations confirm that the mechanism of production of renal damage by cephaloridine, by cephaloridine-glycerol-frusemide and by mercuric chloride differs from that by glycerol alone. The pathological changes are also different; with the first three insults, the ATN involves mainly the proximal convoluted tubules Di Bona et al., 1971) , while in the glycerol model the distal convoluted tubules, Henle's loop and the collecting ducts are also involved (Suzuki & Mostofi, 1970) .
Oliver, Macdowell & Tracy (1951) originally distinguished on histological grounds two broad categories of ARF-'toxic' and 'circulatory'. This classification has also been used by Brown, Gleadle, Lawson, Lever, Linton, Macadam, Prentice, Robertson & Tree (1 970), who concluded from the available evidence that the renin-angiotensin system may be ultimately involved in the 'circulatory' form of ARF in man. Since it is likely that the glycerol model of ARF in rats closely resembles 'circulatory 'ARF in man, this view was supported by the demonstration by McDonald, Thiel, Wilson, Di Bona & Oken (1969) that salt-loaded rats were protected against glycerol-induced renal damage. It was suggested that this effect might be related to the suppression of renin production and thereby avoidance of the prolonged afferent arteriolar vasoconstriction thought to be chiefly responsible for the resulting ARF. Further evidence came from the demonstration by Powell-Jackson, Brown, Lever, Macgregor, Macadam, Titterington, Robertson & Waite (1972) angiotensin I1 conferred protection against glycerol-induced ARF. That renin might also be involved in the pathophysiology of 'toxic' types of ARF was suggested by studies showing that salt-loaded rats were protected against experimental ARF induced by dichromate (Henry, Lane & Kashgarian, 1968) and mercuric chloride (Di Bona et al., 1971) .
In an earlier study it was suggested that nephrotoxic doses of cephaloridine might stimulate renin production, thus explaining the enhancement of cephaloridine nephrotoxicity by concurrent administration of frusemide (Linton et al., 1972) , since this diuretic powerfully stimulates renin release (Skinner, Naughton & Bertoncello, 1972) . Subsequent work has not confirmed this (A. F. Lever, personal communication) . The present series of experiments was designed to test the hypothesis that repeated stimulation with frusemide might exhaust the renin-angiotensin system and thus confer protection against subsequent nephrotoxic insult, if that insult operated by stimulating excess renin release. Striking protection against renal damage due to cephaloridine or mercuric chloride was demonstrated, but the original concept of the mechanism was not supported by the finding that PRA was considerably higher at time of challenge in the frusemide pretreated rats. Furthermore, protection against ATN was still evident when the number of pre-challenge doses of frusemide was reduced to one, and when the dose of frusemide was reduced to 10 mg/kg. It might have been expected that a single pre-challenge dose of frusemide would have increased PRA levels and aggravated damage. Finally, pretreatment with frusemide increased nephrotoxicity in the glycerol model, which is probably closest to the 'circulatory' type of ARF seen in man; in this experiment, PRA levels were the same in control and pretreated animals.
Preliminary studies have shown that a single pretreatment injection of frusemide confers greater protection against renal damage induced by the triple challenge or by cephaloridine alone than does salt-loading rats (1% saline replacing drinking water) for 4 weeks, with or without the addition of deoxycorticosterone acetate-i.e. rats with depleted intrarenal renin (R. R. Bailey, R. Natale, M. A. Homenuik, D. I. Turnbull &A. L. Linton, unpublished work). Such salt-loaded rats have been shown to have suppressed PRA and degranulation of the juxtaglomerular cells when assessed by the Hartcroft & Hartcroft (1953) technique. This aspect has not been fully resolved in this study, but we have found that frusemide pretreatment does not result in degranulation of the juxtaglomerular cells. The significant differences between frusemide pretreated and control rats at the time of challenge were that the former group were moderately dehydrated, had lower serum potassium levels, an elevated PRA and a lower GFR; these factors would all be expected to increase subsequent renal damage, yet this occurred only in the glycerol ('circulatory') model. The conflicting effects of pretreatment with frusemide in 'toxic' ARF compared with 'circulatory' ARF suggests that the pathological mechanisms are different. The marked protective effect of frusemide in the 'toxic' varieties of experimental ARF does not seem to be related to interference with the renin-angiotensin system, and the evidence would suggest that this system is not involved in the pathophysiology of 'toxic' ARF. By inference, this casts doubt on the suggested action of salt-loading in protecting against dichromate or mercuric chloride induced ARF (Di Bona et al., 1971) . The aggravation of glycerol-induced renal damage by pretreatment with frusemide is compatible with the hypothesis that excessive stimulation of renin is involved in the production of 'circulatory' ARF, although we did not demonstrate elevated PRA levels. We did not, however, investigate the possibility that if the renin mechanism acts in the pathogenesis of ARF, it does so intrarenally (Flamenbaum, Kotchen & Oken, 1972) .
The explanation of the protective effect of frusemide in 'toxic' varieties of ARF is not obvious. Chronic administration of frusemide in man has been shown to produce effects similar to those observed in the rat-a fall in extracellular water, a rise in blood urea and a fall in GFR (Jewkes, Burki & Guz, 1970) . In acute experiments in dogs, the infusion of frusemide into the renal artery has been shown to increase outer renal cortical blood flow (Birtch, Zakheim, Jones & Barger, 1967) , but this effect might have been expected to protect against 'circulatory' ARF rather than 'toxic' (Hollenberg, Epstein, Rosen, Basch, Oken & Merrill, 1968) . The mechanism of cephaloridine nephrotoxicity is uncertain. Radioautographic studies have demonstrated the presence of the drug in the renal medullary interstitium and to a lesser extent at the periphery of the proximal renal tubular cells (Currie, Little & McDonald, 1966) ; the renal damage that results from cephaloridine is localized predominantly to the latter side and is presumably due to toxic levels of the drug.
In support of the observation that tubular transport mechanisms are involved in cephaloridine nephrotoxicity is the observation (Fleming & Jaffe, 1967 ) that the administration of probenecid 30 min before an injection of 200 mg/kg of cephalaridine to rabbits prevented the development of ARF and the appearance of protein and casts in the urine. In the present study the serum half-life of cephaloridine in the pretreated groups (after both the triple challenge and cephaloridine, 1500 mg/kg) was slightly prolonged compared with the control groups, probably as a result of the lower GRF in the former groups. Of interest was the tendency for the pretreated group of rats to excrete a higher % of the administered dose of cephaloridine during the following 24 h period. We have not excluded the possibility, however, that the pretreated group of rats had a higher concentration of cephaloridine in the urine in the early hours after the nephrotoxic challenges.
The explanation of these observations must account for the apparent biphasic effect of frusemide on cephaloridine nephrotoxicity-namely, protection against cephaloridine-induced ATN (and slight ARF) if frusemide is given from 5 to 12 h before the cephaloridine, and potentiation when the two drugs are given simultaneously. The observation that pretreatment with frusemide protects against 'toxic' forms of ARF may have some relevance when known nephrotoxic drugs have to be used, and the aggravation of 'circulatory' ARF by frusemide suggests that diuretics should be used with caution in humans with ARF (Cantarovich, Locatelli, Fernandez, Loredo & Cristhot, 1971 ; Stott, Cameron, Ogg & Bewick, 1972) .
